GPCR Signaling Bias ON DEMAND Webinar. A Valuable & Accessible Property of New Drug Candidates. Presented by Terry Kenakin, Ph.D., Prof. of Pharmacology, U. N. Carolina, School of Medicine, Chapel Hill, NC, USA. This webinar explains the biological basis of signaling bias, shows how to detect and quantify it using reliable functional assays, and discusses how these data can guide lead selection and optimization. Practical assay strategies, interpretation pitfalls, and the value of comparing pathway outputs quantitatively, rather than relying on potency alone, sit at the center of the session.

Discover how High-throughput Spectral Shift (HT-SpS) technology accelerates binder and molecular glue discovery for some of the most challenging targets, including proteins with allosteric sites and complex protein–protein interactions.

Novel Alternative Methods (NAMs) are emerging as an important strategy for improving the success rate in drug discovery.

Obesity is a complex, multifactorial disease that presents major hurdles for drug discovery and development.

The need for efficient and innovative drug discovery chemistry strategies to support novel modalities like Degraders, ADCs (Antibody-Drug Conjugates), and other complex therapeutics has never been greater.

Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Discover how in vitro and computational tools reduce the reliance on animal testing and support smarter, earlier decision-making in drug discovery.